MarketCap
Facebook
X
Telegram
Royalty Pharma plc Income Statement 2025-2011 | RPRX
Brief overview of revenue and earnings at Royalty Pharma plc
The figures are compared over a five-year interval. According to figures from Royalty Pharma plc, revenue changed from 2.1 billion dollars to 2.4 billion dollars over five years. The five-year change reached +12.1%, while CAGR stood at 2.3%. The revenue trend is close to stagnation.
Over the period, EBITDA shifted from $1.6 billion to $1.6 billion, a change of −3.4%. The operating result developed less favorably than sales. Comparing the endpoints gives EBITDA margins of 76.3% and 65.7%. Cost pressure reduced operating profitability.
The net result moved from 975 million dollars to 771 million dollars, or −20.9%. The business generated less net income by the end of the period.
The five-year change in capitalization reached +9.2%: from $17.4 billion to $18.9 billion. Market value followed a broadly neutral trajectory.
Conclusion
The indicators point to a weaker financial profile. The overall view is constrained by a weaker final result, a declining EBITDA margin and weak sales momentum. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Royalty Pharma plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
18.9 B | 14.5 B | 13.4 B | 16.5 B | 16.3 B | 17.4 B | - | - | - | - | - | - | - | - | - |
Shares |
430 M | 448 M | 448 M | 438 M | 415 M | 375 M | - | - | - | - | - | - | - | - | - |
Historical Prices |
44.1 | 32.4 | 30 | 37.8 | 39.3 | 46.2 | - | - | - | - | - | - | - | - | - |
Net Income |
771 M | 859 M | 1.13 B | 42.8 M | 620 M | 975 M | 2.35 B | 1.38 B | 1.21 B | - | - | - | - | - | - |
Revenue |
2.38 B | 2.26 B | 2.35 B | 2.24 B | 2.29 B | 2.12 B | 1.79 B | 1.66 B | 1.58 B | - | - | - | - | - | - |
Operating Income |
1.56 B | 1.29 B | 1.49 B | 307 M | 1.43 B | 1.6 B | 2.62 B | 1.36 B | - | - | - | - | - | - | - |
Interest Expense |
-14.3 M | -1.53 M | 187 M | 188 M | 166 M | 157 M | 269 M | 280 M | - | - | - | - | - | - | - |
EBITDA |
1.56 B | 1.29 B | 1.49 B | 313 M | 1.45 B | 1.62 B | 2.65 B | 1.4 B | 973 M | - | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | - | -829 M | 294 M | 638 M | - | - | - | - | - | - |
General and Administrative Expenses |
573 M | 237 M | 250 M | 227 M | 183 M | 182 M | 103 M | 61.9 M | 106 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Royalty Pharma plc
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
445 M | 437 M | 432 M | 424 M | 435 M | 448 M | 451 M | 449 M | 448 M | 450 M | 446 M | - | 439 M | 436 M | 434 M | - | 428 M | 409 M | 390 M | - | 370 M | 354 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
17.9 M | 295 M | 288 M | 30.2 M | 238 M | 544 M | 102 M | 4.78 M | 72.1 M | 228 M | 341 M | - | 143 M | 305 M | 51.8 M | - | 102 M | 441 M | 69.1 M | - | 291 M | 442 M | 71.2 M | - | 409 M | 152 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
674 M | 631 M | 609 M | 579 M | 568 M | 565 M | 537 M | 568 M | 536 M | 538 M | 684 M | - | 573 M | 536 M | 562 M | - | 586 M | 555 M | 573 M | - | 538 M | 511 M | 501 M | - | 464 M | 458 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
133 M | 563 M | 427 M | 210 M | 534 M | 735 M | 270 M | -73.8 M | 151 M | 249 M | 479 M | - | 192 M | 378 M | 220 M | - | 303 M | 745 M | 229 M | - | 511 M | 409 M | 361 M | - | 532 M | 328 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-1.5 M | -2.2 M | -1.58 M | -1.54 M | -3.06 M | -1.65 M | 6 M | -3.68 M | -1.71 M | 1.09 M | 47 M | - | 47 M | 47 M | 47.1 M | - | 44.3 M | 37.4 M | 37.4 M | - | 31.4 M | 34.2 M | 53.6 M | - | 68.8 M | 69.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
136 M | 564 M | - | - | - | - | - | - | - | - | - | - | 192 M | 378 M | 225 M | - | 309 M | 751 M | 235 M | - | 516 M | 415 M | 367 M | - | 538 M | 334 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
162 M | 159 M | 119 M | 180 M | 111 M | 56.7 M | 54.7 M | 57.7 M | 57.2 M | 47.6 M | 85.7 M | - | 50.7 M | 51.8 M | 51.5 M | - | 48.6 M | 44.9 M | 43.2 M | - | 50.7 M | 42.8 M | 38.1 M | - | 25.6 M | 30.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Royalty Pharma plc (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
